Cite
HARVARD Citation
Ostadal, P. et al. (2022). Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet. 10 (5), pp. 330-340. [Online].